- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Distinguishing Sedation VS Efficacy In Antipsychotic Treatment

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Distinguishing Sedation VS Efficacy In Antipsychotic Treatment
In this presentation, the objectives are to:
- To recognize the symptoms of acute agitation in an emergency department setting
- To understand the potential importance of minimizing sedation in the treatment of acute agitation in patients with schizophrenia
- To distinguish sedation from efficacy in antipsychotic treatment
- To understand the physiologic mechanisms for sedation and pharmacologic considerations when selecting an antipsychotic

Stephen R. Saklad, PharmD, BCPP
Director, Psychiatric Pharmacy Program, UT Health Science Center San Antonio; Clinical Professor, UTHSCSA, School of Medicine, Pharmacotherapy Education & Research Center, The University of Texas at Austin College of Pharmacy; and Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services
More

Dennis Pabis, PharmD, BCPP (OPDC)
Senior Medical Science Liaison
Speaker Stephen R Saklad, PharmD, BCPP is a paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.
Speaker Dennis Pabis, PharmD, BCPP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.